Lou et al. found that MMC enhanced the effect of PD-L1 blocking in non-small cell lung cancer cells and that combined treatment with MMC and PD-L1 antibodies in in vitro mouse models was more beneficial to tumor development and overall survival [22]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.